Brief: Ribomic Announces Positive Top-Line Results From The Phase 1/2A Clinical Trial Of Rbm-007

Ribomic

17/06/2019 17:49

June 17 (Reuters) - Ribomic Inc  4591.T :
    * RIBOMIC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE PHASE
1/2A
CLINICAL TRIAL OF RBM-007 (SUSHI STUDY) IN SUBJECTS WITH WET
AGE-RELATED MACULAR DEGENERATION
    * RIBOMIC INC - RBM-007 WAS WELL-TOLERATED WITH NO
DOSE-LIMITING
TOXICITIES, NO SYSTEMIC OR OCULAR SERIOUS ADVERSE EVENTS.
    * RIBOMIC INC - SEVEN OUT OF NINE SUBJECTS SHOWED EVIDENCE
OF
RBM-007 BIOACTIVITY
    * RIBOMIC INC - SUSHI STUDY ACHIEVED PRIMARY ENDPOINT OF
SAFETY
AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR
OF RBM-007.
    * RIBOMIC INC - PLANNING FOR NEXT MULTI-DOSE PHASE 2
CLINICAL
TRIAL IS UNDERWAY AND ENROLLMENT IS EXPECTED TO BEGIN IN 3Q OF
FY2019.

Source text for Eikon:  ID:nBw2Kjc4Ra 
Further company coverage:  4591.T 

 ((Reuters.Briefs@thomsonreuters.com;))